Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833833 · ClinicalTrials.gov registry record · Phase 1
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
A Phase 1 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 259
- Enrollment target
NCT00833833 is a Phase 1 study that has completed, run by Celgene Corporation. The registered enrollment target is 259 participants.
The verdict
NCT00833833, a Phase 1 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 259 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose and effectiveness of the study drug (CC-4047) Alone Or in Combination With Low-dose Dexamethasone as treatment for patients with relapsed and refractory multiple myeloma
Interventions
- DRUG Aspirin
- DRUG Dexamethasone
- DRUG Pomalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2008-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833833
The ClinicalTrials.gov registry entry for NCT00833833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aspirin is the first listed.
NCT00833833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833833 about?
NCT00833833 is a clinical study titled "MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma". The purpose of this study is to determine the maximum tolerated dose and effectiveness of the study drug (CC-4047) Alone Or in Combination With Low-dose Dexamethasone as treatment for patients with relapsed and refractory multiple myeloma
What is the current status of trial NCT00833833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 259 participants. The study started on 2008-06. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00833833?
The interventions under investigation include: Aspirin (DRUG), Dexamethasone (DRUG), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT00833833?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.